Drug Search Results
More Filters [+]

Tregalizumab

Alternative Names: tregalizumab, bt-061, bt061, bt 061
Latest Update: 2022-02-08
Latest Update Note: Clinical Trial Update

Product Description

Mechanisms of Action: CD4 Inhibitor

Novel Mechanism: Yes

Modality: Antibody

Route of Administration: N/A

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Biotest AG
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Tregalizumab

Countries in Clinic: Germany

Active Clinical Trial Count: 2

Highest Development Phases

Phase 2: Asthma, Allergic|Dust mite Hypersensitivity|Environmental Hypersensitivity|Inflammation

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

Tregulaire

P2

Completed

Dust mite Hypersensitivity|Environmental Hypersensitivity|Asthma, Allergic|Inflammation

2022-01-12

35%

Tregulaire

P2

Completed

Environmental Hypersensitivity|Asthma, Allergic|Dust mite Hypersensitivity

2022-01-12

Recent News Events

Date

Type

Title